Cargando…
Caveat emptor: the combined effects of multiplicity and selective reporting
Clinical trials and systematic reviews of clinical trials inform healthcare decisions. There is growing concern, however, about results from clinical trials that cannot be reproduced. Reasons for nonreproducibility include that outcomes are defined in multiple ways, results can be obtained using mul...
Autores principales: | Li, Tianjing, Mayo-Wilson, Evan, Fusco, Nicole, Hong, Hwanhee, Dickersin, Kay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142307/ https://www.ncbi.nlm.nih.gov/pubmed/30223876 http://dx.doi.org/10.1186/s13063-018-2888-9 |
Ejemplares similares
-
Caveat emptor
por: Aswani, Yashant, et al.
Publicado: (2015) -
Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events
por: Mayo-Wilson, Evan, et al.
Publicado: (2019) -
Shorter course of trastuzumab: Caveat emptor
por: Venniyoor, Ajit
Publicado: (2011) -
New implants in orthopaedics – caveat emptor
por: Warwick, D, et al.
Publicado: (2012) -
Caveat emptor: for researchers, a rose will not smell sweet unless we know its composition
por: Adams, Josephine C.
Publicado: (2017)